These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17270031)

  • 1. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
    Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
    Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice.
    Couper KN; Blount DG; de Souza JB; Suffia I; Belkaid Y; Riley EM
    J Immunol; 2007 Apr; 178(7):4136-46. PubMed ID: 17371969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
    Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
    Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative methodologies of regulatory T cell depletion in a murine melanoma model.
    Matsushita N; Pilon-Thomas SA; Martin LM; Riker AI
    J Immunol Methods; 2008 Apr; 333(1-2):167-79. PubMed ID: 18295790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
    Tan C; Reddy V; Dannull J; Ding E; Nair SK; Tyler DS; Pruitt SK; Lee WT
    J Transl Med; 2013 Jun; 11():148. PubMed ID: 23768240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.
    Satoh Y; Esche C; Gambotto A; Shurin GV; Yurkovetsky ZR; Robbins PD; Watkins SC; Todo S; Herberman RB; Lotze MT; Shurin MR
    J Exp Ther Oncol; 2002; 2(6):337-49. PubMed ID: 12440225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
    Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
    Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.
    Teng MW; Ngiow SF; von Scheidt B; McLaughlin N; Sparwasser T; Smyth MJ
    Cancer Res; 2010 Oct; 70(20):7800-9. PubMed ID: 20924111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
    Takaku S; Terabe M; Ambrosino E; Peng J; Lonning S; McPherson JM; Berzofsky JA
    Int J Cancer; 2010 Apr; 126(7):1666-74. PubMed ID: 19830696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
    Setiady YY; Coccia JA; Park PU
    Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61.
    McNeill A; Spittle E; Bäckström BT
    Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.